Breast Cancer — Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
Citation(s)
A Phase I/II Study of Foretinib in Combination With Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2(HER2)Over-Expressing Metastatic Breast Cancer